Drug intelligence / Profile preview

LP-00A

Development stage: Preclinical
Lead developer: Longbio Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

LP-00A is a preclinical-stage bi-functional antibody being developed by Longbio Pharma for the treatment of allergic diseases. It is generated using Longbio's proprietary bi-functional antibody platform, which is designed to create molecules with structural flexibility for targeting complex immunological pathways. While the specific biological targets of LP-00A have not been publicly disclosed, the candidate is part of a pipeline focused on allergic and autoimmune conditions, aiming to provide improved therapeutic options over conventional monoclonal antibodies.

Beyond the preview

Go deeper on LP-00A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LP-00A.

Explore the full profile